You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.
The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
The results of this meta-analysis by University of Cambridge-led team could have implications for LDL-C-lowering therapies.
Researchers saw both short- and long-term changes in metabolite profiles in blood plasma from individuals who'd undergone Roux-en-Y gastric bypass surgery.
Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.
The core technology uses proximity-ligated amplification and the firm will build it into tests for type I diabetes as well as highly multiplexed assays.
In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.
University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.
In Nature this week: rare variants contribute little risk to type 2 diabetes, atlas of gene expression in developing primate brain, and more.
Genomic data for more than 125,000 individuals uncovered type 2 diabetes risk variants, many appearing at loci identified through common variant association studies.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.